Galimedix Therapeutics
Galimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing proprietary small-molecule and prodrug therapies that modulate amyloid-beta aggregation for the treatment of Alzheimer's disease and related brain and eye disorders.
- Company typePrivate
- Founded2018
- HeadquartersKensington, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Galimedix Therapeutics does
Galimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing neuroprotective therapies for brain and eye diseases, founded in 2018 and headquartered in Kensington, United States. The company's core technology centers on amyloid-beta aggregation modulation, with proprietary small-molecule compounds designed to address pathologies associated with Alzheimer's disease and related CNS and ocular conditions. Its disclosed portfolio consists of two drug candidates: GAL-101, a small molecule targeting misfolded amyloid beta that has completed Phase 1 trials in approximately 100 healthy volunteers, demonstrating safety, tolerability, and blood-brain barrier penetration and is being advanced to Phase 2 for Alzheimer's disease; and GAL-201, a next-generation oral prodrug in preclinical development with improved pharmacokinetic properties, including rapid absorption, higher peak plasma concentrations, and enhanced oral bioavailability relative to the parent compound.
The company operates a research-driven development model typical of clinical-stage biopharmaceutical firms, with no commercially approved products and therefore no product-revenue mechanics in place. Its target patient population is individuals requiring long-term treatment for Alzheimer's disease, with an explicit design focus on formulations that enable lower dosing and improved patient adherence. Galimedix has been actively engaging the scientific community through conference presentations at major neurodegenerative disease forums, including CTAD 2025 and AD/PD 2026, signaling continued pipeline progression and visibility within the Alzheimer's research ecosystem.
With a small team of 1-10 employees, Galimedix operates a lean structure typical of early-stage biotechs and is supported by at least one disclosed institutional backer, InFocus Capital Partners, following a 2020 financing. The strategic positioning emphasizes advancing GAL-101 through Phase 2 clinical trials while developing GAL-201 as a next-generation follow-on, indicating a portfolio approach to amyloid-beta targeting across clinical and preclinical stages. Pricing, licensing economics, and commercial go-to-market channels are not applicable at the current development stage.
Galimedix Therapeutics firmographics
Firmographics- Name
- Galimedix Therapeutics
- Website
- https://galimedix.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Galimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing proprietary small-molecule and prodrug therapies that modulate amyloid-beta aggregation for the treatment of Alzheimer's disease and related brain and eye disorders.
- Ownership category
- akta.pro rank
Galimedix Therapeutics industry classification
Industry- Product category
- Ophthalmic & Neuro Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
- akta.pro secondary industry
- Rare Ophthalmology Disorder Therapies (HLAIAIAK)
Keywords
Where Galimedix Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Kensington
- HQ country
- United States
- HQ region
- North America
Markets served
Galimedix Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Galimedix Therapeutics product offering
Product offeringCore offering
Galimedix Therapeutics develops proprietary small molecule drug candidates (GAL-101 and GAL-201) that target misfolded amyloid beta to treat Alzheimer's disease and related ophthalmic conditions. The lead asset GAL-101 has completed Phase 1 trials demonstrating blood-brain barrier penetration and safety in approximately 100 healthy volunteers, with Phase 2 trials planned in Alzheimer's disease. GAL-201 is a next-generation oral prodrug in preclinical development showing improved pharmacokinetics and lower-dose potential.
Product overview
Galimedix Therapeutics is a Phase 2 clinical-stage biotechnology company developing neuroprotective therapies for brain and eye diseases. The company's product portfolio consists of two amyloid beta-targeting drug candidates: GAL-101 (a small molecule that has completed Phase 1 trials and is advancing to Phase 2 for Alzheimer's disease) and GAL-201 (a next-generation oral prodrug candidate in preclinical development with improved pharmacokinetic properties for potential lower-dose treatment). Both compounds target amyloid beta pathology associated with Alzheimer's disease.
Differentiator
Problem solved
Functional benefit
Products and services
- GAL-101 Small molecule drug candidate targeting misfolded amyloid beta. Completed Phase 1 clinical study in approximately 100 healthy volunteers, demonstrating safety, tolerability, and effective blood-brain barrier penetration. Advancing to Phase 2 trials for Alzheimer's disease treatment.
- GAL-201 Next-generation oral Alzheimer's disease drug candidate; an amyloid-beta aggregation modulator prodrug showing higher absorption and systemic concentration with improved pharmacokinetics (rapid absorption, higher peak plasma concentrations, better oral bioavailability) compared to the parent compound. Designed for lower dosing to improve patient compliance in long-term treatment.
Quantifiable outcome
- Significantly improved pharmacokinetic profile with rapid absorption, higher peak plasma concentrations, and better oral bioavailability compared to parent compound
- +2 more outcomes
Companies that use Galimedix Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Galimedix Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Galimedix Therapeutics partnerships and signals
Strategic signalScale indicators2 records
Recent moves4 records
Expansion highlights3 records
Galimedix Therapeutics competitors and assessment
Company assessmentDirect peers
- Anavex Life Sciences: Clinical-stage biopharmaceutical company developing oral small-molecule therapies for Alzheimer's and other neurodegenerative diseases. Highly comparable to Galimedix in modality (oral small molecule), indication focus (Alzheimer's), and stage (Phase 2/3 clinical).
- Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Similar in therapeutic focus (Alzheimer's), clinical stage, and small-cap public/private biotech profile, though Cassava's mechanism is non-amyloid.
- AC Immune: Swiss clinical-stage biotech focused on therapeutics and diagnostics targeting amyloid-beta and Tau in neurodegenerative diseases. Directly comparable as an amyloid-targeting pipeline peer in the Alzheimer's space.
- Prothena Corporation: Clinical-stage biotech developing antibody-based therapies for amyloid-related diseases including Alzheimer's and Parkinson's. Comparable amyloid-beta pipeline focus with clinical-stage assets.
- Cognition Therapeutics: Clinical-stage biotech developing oral small-molecule drugs that target amyloid-beta oligomers for Alzheimer's disease and related dementias. Highly comparable to Galimedix in modality, target (Aβ oligomers), and clinical stage.
- Alzheon: Clinical-stage biotech developing oral small-molecule therapies that inhibit amyloid-beta oligomer formation for early Alzheimer's disease. Closely comparable to Galimedix in mechanism, modality (oral small molecule), and clinical stage.
Emerging players
- Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases, including small molecules and biologics crossing the blood-brain barrier. Comparable neurodegeneration focus with a BBB-penetration platform similar in concept to Galimedix's approach.
- Alector: Clinical-stage biotech developing immuno-neurology treatments for Alzheimer's and frontotemporal dementia. Comparable neurodegenerative focus and clinical-stage profile, with partnerships involving large pharma.
Broad incumbents
- Eisai (Leqembi): Large pharmaceutical company that co-developed Leqembi (lecanemab), the leading approved anti-amyloid antibody for Alzheimer's disease with Biogen. Sets the competitive benchmark any new amyloid-beta therapy must surpass.
- Eli Lilly (Kisunla/donanemab): Large pharmaceutical company with Kisunla (donanemab), an approved anti-amyloid antibody for Alzheimer's. Represents the dominant commercial competitor in the amyloid-beta space that any Galimedix asset would face.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Galimedix Therapeutics social profiles
Digital presenceGalimedix Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Galimedix Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Galimedix Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Galimedix Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Galimedix Therapeutics
What does Galimedix Therapeutics do?
Galimedix Therapeutics develops proprietary small molecule drug candidates (GAL-101 and GAL-201) that target misfolded amyloid beta to treat Alzheimer's disease and related ophthalmic conditions. The lead asset GAL-101 has completed Phase 1 trials demonstrating blood-brain barrier penetration and safety in approximately 100 healthy volunteers, with Phase 2 trials planned in Alzheimer's disease. GAL-201 is a next-generation oral prodrug in preclinical development showing improved pharmacokinetics and lower-dose potential.
Is Galimedix Therapeutics a public or private company?
Galimedix Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Galimedix Therapeutics founded?
Galimedix Therapeutics was founded in 2018. It employs 1 to 10 people.
Where is Galimedix Therapeutics based?
Galimedix Therapeutics is headquartered in Kensington, United States, in the North America region.
Who are Galimedix Therapeutics's main competitors?
Direct peers on record are Anavex Life Sciences, Cassava Sciences, AC Immune, Prothena Corporation, Cognition Therapeutics and Alzheon. Emerging players are Denali Therapeutics and Alector. Broad incumbents are Eisai (Leqembi) and Eli Lilly (Kisunla/donanemab).
Does Galimedix Therapeutics have an API?
No public API is recorded for Galimedix Therapeutics.
What industry is Galimedix Therapeutics in?
Galimedix Therapeutics's product category is Ophthalmic & Neuro Pharmaceuticals. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAIAIAK, Rare Ophthalmology Disorder Therapies. Its NAICS code is 541714 and its SIC code is 3851.